|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cytomx Therapeutics, Inc. (CTMX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
65,160,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
47,819 |
75,591 |
103,916 |
162,805 |
| Total Sell Value |
$99,726 |
$138,068 |
$174,902 |
$267,502 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
10 |
14 |
26 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mccarthy Sean A. |
President and CEO |
• • – |
2017-06-26 |
4 |
OE |
$0.95 |
$4,235 |
D/D |
4,481 |
8,726 |
|
- |
|
| Gluck Frederick W |
Director |
– • – |
2017-06-26 |
4 |
AS |
$14.61 |
$73,050 |
I/I |
(5,000) |
326,643 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-06-05 |
4 |
AS |
$15.00 |
$4,500 |
D/D |
(300) |
4,245 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-06-05 |
4 |
OE |
$0.95 |
$284 |
D/D |
300 |
4,545 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-05-31 |
4 |
A |
$8.68 |
$19,665 |
D/D |
2,266 |
4,245 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2017-05-31 |
4 |
A |
$8.68 |
$23,415 |
D/D |
2,698 |
24,626 |
|
- |
|
| Ray Debanjan |
Chief Financial OfficerOfficer |
• – – |
2017-05-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,928 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2017-05-12 |
4 |
OE |
$4.47 |
$110,700 |
D/D |
19,967 |
32,756 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-05-01 |
4 |
AS |
$15.70 |
$75,062 |
D/D |
(4,781) |
1,979 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-05-01 |
4 |
OE |
$0.95 |
$4,518 |
D/D |
4,781 |
6,760 |
|
- |
|
| Starr Kevin P |
10% Owner |
– – • |
2017-04-12 |
4 |
S |
$16.36 |
$463,793 |
D/D |
(28,357) |
31,419 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2017-04-10 |
4 |
OE |
$4.47 |
$13,418 |
D/D |
3,000 |
12,789 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-04-04 |
4 |
AS |
$17.50 |
$83,668 |
D/D |
(4,781) |
1,979 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-04-04 |
4 |
OE |
$0.95 |
$4,518 |
D/D |
4,781 |
6,760 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-04-03 |
4 |
AS |
$16.94 |
$80,990 |
D/D |
(4,781) |
1,979 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-04-03 |
4 |
OE |
$0.95 |
$4,518 |
D/D |
4,781 |
6,760 |
|
- |
|
| Canaan Partners Ix Llc |
Director |
– • – |
2017-03-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(750,000) |
2,494,381 |
|
- |
|
| Exter Neil |
Director |
– • – |
2017-03-27 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2017-03-27 |
4 |
S |
$18.00 |
$11,700,195 |
D/D |
(650,000) |
5,170,348 |
|
- |
|
| Exter Neil |
Director |
– • – |
2017-03-23 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2017-03-23 |
4 |
S |
$17.00 |
$17,000,200 |
D/D |
(1,000,000) |
5,820,348 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2017-03-20 |
4 |
AS |
$19.60 |
$426,340 |
D/D |
(21,517) |
9,789 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2017-03-20 |
4 |
OE |
$4.47 |
$96,241 |
D/D |
21,517 |
31,306 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-03-20 |
4 |
AS |
$19.60 |
$281,123 |
D/D |
(14,343) |
1,979 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-03-20 |
4 |
OE |
$0.95 |
$13,554 |
D/D |
14,343 |
16,322 |
|
- |
|
286 Records found
|
|
Page 8 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
